<?php
include_once('.././common.php');
include_once(G5_PATH.'/head.php');
?>

<div id="providers" class="sub02">
	<section class="sub-visual visual02 el">
		<div class="visual-txt">
			<h2><?=$title?></h2>
		</div>
	</section>
	<!--sub-visual-->
	<section id="sec01" class="cont-a el">
		<div class="inner">
			<h2 class="cont-tit">Phase I 1.1 Healthy Volunteer Study (NCT04525079)<span>¹</span></h3>
			<div class="cont-sec">
				<h3 class="sub-tit">Study Design</h3>
				<ul class="cont-list cont-indt">
					<li>A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study </li>
				</ul>
			</div>
			<div class="img-sec"><img src="/img/providers/des_img01.png"></div>	
			<div class="cont-sec">
				<h3 class="sub-tit">Primary Objective</h3>
				<div class="cont-indt">
					<div class="cont-box">
						<ul class="cont-list">
							<li>To evaluate the preliminary <b>safety and tolerability</b> of regdanvimab up to Day 14 of the last enrolled subject</li>
						</ul>
					</div>
				</div>
			</div>
			<div class="cont-sec">
				<h3 class="sub-tit">Primary Endpoint</h3>
				<div class="cont-indt">
					<div class="cont-box">
						<ul class="cont-list">
							<li>Primary safety outcome [Time Frame: Day 14]</li>
							<li>Treatment-emergent adverse events (TEAEs)</li>
							<li>Treatment-emergent serious AEs (TESAEs)</li>
							<li>Treatment-emergent AEs of special interest (TEAESI; infusion related reactions including hypersensitivity/anaphylactic reaction)</li>
						</ul>
					</div>
				</div>
			</div>
			<!--<div class="cont-sec">
				<h3 class="sub-tit">Key Secondary Endpoints</h3>
				<div class="cont-indt">
					<div class="cont-box">
						<ul class="cont-list">
							<li>Virology : Viral shedding in nasopharyngeal swab specimens based on qPCR and cell culture</li>
							<li>Efficacy : Time to clinical recovery up to Day 28</li>
						</ul>
					</div>
				</div>
			</div>-->
		</div>
	</section>
	<!--cont-a-->
	<section class="cont-b">
		<div class="inner">
			<h3 class="sub-tit">Study Results</h3>
			<h3 class="sub-tit3">Study Demographic</h3>
			<div class="cont-indt">
				<div class="cont-box">
					<ul class="cont-list">
						<li>In general, the demographics were well distributed between the treatment groups.</li>
						<li>All subjects were male and Asian (n = 32; 100%).</li>
					</ul>
				</div>
			</div>
			<h3 class="sub-tit3">Safety</h3>
			<div class="cont-indt">
				<div class="cont-box">
					<ul class="cont-list">
						<li>There were a total of 4 TEAEs in 4 subjects (n = 4; 12.5%) up to Day 14 of the last enrolled subject.</li>
						<li>All TEAEs were considered as related, grade 1 in Intensity and recovered.</li>
						<li>There was 1 TEAESI of infusion related reaction in cohort 3 (n = 1; 12.5%).</li>
						<li>There were no TESAEs or adverse events leading to study discontinuation.</li>
						<li>Overall, regdanvimab was well tolerated in the study population of healthy subjects.</li>
					</ul>
				</div>
				<p class="p-bk">TEAE, treatment-emergent adverse event; TEAESI, treatment-emergent adverse event of special interest; TESAE, treatment-emergent serious adverse event.</p>
			</div>
		</div>
	</section>
	<!--cont-b-->
	<section id="sec02" class="cont-c el">
		<div class="inner">
			<h2 class="cont-tit">Phase I 1.2 Mild COVID-19 Study (NCT04593641)<span>¹</span></h2>
			<div class="cont-sec">
				<h3 class="sub-tit">Study Results</h3>
				<ul class="cont-list cont-indt">
					<li>A Pilot Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study</li>
				</ul> 
			</div>
			<div class="img-sec"><img src="/img/providers/des_img03.png"></div>
			<!--Study Design-->
			<div class="cont-sec">
				<h3 class="sub-tit">Objectives</h3>
				<div class="cont-box cont-indt">
					<ul class="cont-list">
						<li>Primary objective: To evaluate the preliminary <b>safety and tolerability</b> of regdanvimab up to Day 14 of the last enrolled patient</li>
						<li>Secondary objective: To evaluate the <b>viral efficacy and characterization of SARS-CoV-2 viral isolates, efficacy, PK and additional safety</b> 
						of regdanvimab including immunogenicity</li>
					</ul> 
				</div>
			</div>
			<!--Objectives-->
			<div class="cont-sec">
				<h3 class="sub-tit">Primary Endpoints</h3>
				<div class="cont-box cont-indt">
					<ul class="cont-list">
						<li>Primary safety outcome [Time Frame: Day 14]</li>
						<li>Treatment-emergent adverse events (TEAEs)</li>
						<li>Treatment-emergent serious AEs (TESAEs)</li>
						<li>Treatment-emergent AEs of special interest (TEAESI; infusion related reactions including hypersensitivity/anaphylactic reaction)</li>
					</ul>
				</div>
			</div>
			<!--Primary Endpoints-->
			<div class="cont-sec">
				<h3 class="sub-tit">Key Secondary Endpoints</h3>
				<div class="cont-box cont-indt">
					<ul class="cont-list">
						<li>Virology: Viral shedding in nasopharyngeal swab specimens based on qPCR and cell culture</li>
						<li>Efficacy: Time to clinical recovery up to Day 28</li>
					</ul>
				</div>
			</div>
			<!--Key Secondary Endpoints-->
		</div>
	</section>
	<!--cont-c-->
	<section class="cont-d">
		<div class="inner">
			<div class="cont-sec">
				<h3 class="sub-tit">Study Results</h3>
				<h3 class="sub-tit3">Study Demographics</h3>
				<div class="cont-box cont-indt">
					<ul class="cont-list">
						<li>
							Median age was slightly higher in the regdanvimab 20 mg/kg group (59.0 years compared to 52.0 years in all patients), 
							but in general the demographics were well matched between the treatment groups.
						</li>
						<li>All patients in cohort 1 were Asian and all patients in cohort 2 and 3 were Caucasian.</li>
					</ul>
				</div>
			</div>
			<!--Study Demographics-->
			<div class="cont-sec">
				<h3 class="sub-tit3">Safety</h3>
				<div class="cont-box cont-indt">
					<ul class="cont-list">
						<li>There were a total of 19 TEAEs in 11 subjects (n = 11 [61.1%]) up to Day 14 of the last enrolled patient.</li>
						<li>All TEAEs were considered as unrelated.</li>
						<li>There were no TESAEs, TEAESI or adverse events leading to study discontinuation.</li>
						<li>Overall, regdanvimab was well tolerated in the study population of patients with mild SARS-CoV-2 infection.</li>
					</ul>
				</div>
			</div>
			<!--Safety-->
			<div class="cont-sec">
				<h3 class="sub-tit3">Time to Clinical Recovery up to Day 14</h3>
				<div class="cont-box cont-indt">
					<ul class="cont-list">
						<li><b>Time to clinical recovery was <span class="p-gr">7 days</span> in Placebo and <span class="p-gr">3.5 day</span> in regdanvimab 40mg/kg arm.</b></li>
					</ul>
					<div class="table-wr">
						<table class="table-style02">
							<thead>
								<tr>
									<th colspan="2">Category</th>
									<th>Placebo<br>(N=3)</th>
									<th>regdanvimab<br>20 mg/kg (N=5)</th>
									<th>regdanvimab<br>40 mg/kg (N=5)</th>
									<th>regdanvimab<br>80 mg/kg (N=5)</th>
									<th>regdanvimab Total<br>(N=15)</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td class="cate"><b>Age(years)</b></td>
									<td class="cate">Median (range)</td>
									<td>50.0 (49, 57)</td>
									<td>59.0 (49, 61)</td>
									<td>51.0 (25, 52)</td>
									<td>52.0 (29, 59)</td>
									<td>54.0 (25, 61)</td>
								</tr>
								<tr>
									<td class="cate"><b>Time from symptom onset to study drug<br>administration (days)</b></td>
									<td class="cate">Median (range)</td>
									<td bgcolor="#f7f7f7">3 (2,4)</td>
									<td bgcolor="#f7f7f7">3 (2,4)</td>
									<td bgcolor="#f7f7f7">5 (3,6)</td>
									<td bgcolor="#f7f7f7">3 (2,5)</td>
									<td bgcolor="#f7f7f7">3 (2,6)</td>
								</tr>
								<tr>
									<td class="cate" rowspan="2"><b>Time to clinical recovery (days)</b></td>
									<td class="cate">Mean</td>
									<td><b class="p-rd">7</b></td>
									<td><b class="p-rd">4.7</b></td>
									<td><b class="p-rd">3.5</b></td>
									<td><b class="p-rd">3.5</b></td>
									<td><b class="p-rd">3.9</b></td>
								</tr>
								<tr>
									<td class="cate">Median (range)</td>
									<td>2 (1, 18)</td>
									<td>4.0 (2.0, 7.5)</td>
									<td>2.0 (0.5, 8.5)</td>
									<td>3.5 (1.5, 5.5)</td>
									<td>3.5 (0.5, 8.5)</td>
								</tr>
								<tr>
									<td class="cate"><b>Hospitalization or antiviral therapy<br>due to aggravation of COVID-19</b></td>
									<td class="cate">N/Total N (%)</td>
									<td>1/3 (33.3%)</td>
									<td>0</td>
									<td>0</td>
									<td>0</td>
									<td>0</td>
								</tr>
							</tbody>
						</table>
					</div>
					<ul class="cont-list">
						<li>
							Clinical recovery is defined by all symptoms on the SARS-CoV-2 infection symptom Checklist (consists of 7 symptoms and the intensity of patient’s self-aware for each. symptom) are recorded as ‘absent or mild in intensity’ for at least 24 hours.
						</li>
						<li>Regdanvimab is not authorized with doses of 20 mg/kg and 80 mg/kg.</li>
						<li class="blt-none"><b class="p-bk">TEAE, treatment-emergent adverse event; TEAESI, treatment-emergent adverse event of special interest.</b></li>
					</ul>
				</div>
			</div>
			<!---->
			<div class="cont-sec">
				<h3 class="sub-tit3">Viral shedding based on qPCR up to Day 7 (N=18)</h3>
				<div class="cont-box cont-indt">
					<ul class="cont-list">
						<li>The mean changes from baseline for viral shedding in nasopharyngeal swab specimens based on qPCR in the regdanvimab treatment groups were generally greater than the Placebo group.</li>
						<li>In general, patients with max viral titer over 5 log10cp/mL based on qPCR had greater reductions in viral shedding up to Day 7 after receiving regdanvimab than Placebo.</li>
					</ul>
					<div class="img-sec"><img src="/img/providers/graph_img01.jpg"></div>
					<div class="table-wr">
						<table class="table-style02">
							<thead>
								<tr>
									<th colspan="2"></th>
									<th>&lt;10^5 cp/mL (N=<span class="p-bl">0</span>/<span class="p-dgr">3</span>/<span class="p-rd">1</span>/<span class="p-bk">2</span>)</th>
									<th>&gt;10^5 cp/mL (N=<span class="p-bl">5</span>/<span class="p-dgr">2</span>/<span class="p-rd">4</span>/<span class="p-bk">1</span>)</th>
									<th>&gt;10^6 cp/mL (N=<span class="p-bl">4</span>/<span class="p-dgr">2</span>/<span class="p-rd">3</span>/<span class="p-bk">1</span>)</th>
									<th>&gt;10^7cp/mL (N=<span class="p-bl">3</span>/<span class="p-dgr">2</span>/<span class="p-rd">3</span>/<span class="p-bk">1</span>)</th>
								</tr>
							<thead>
							<tbody>
								<tr>
									<td class="cate" rowspan="4">Mean value<br>of max viral titer<br>(+-SE in log<span class="sb-script">10</span> cp/ml)</td>
									<td>regdanvimab 20 mg/kg</td>
									<td>N/A</td>
									<td>6.74 (0.388)</td>
									<td>7.09 (0.239)</td>
									<td>7.30 (0.148)</td>
								</tr>
								<tr>
									<td>regdanvimab 40 mg/kg</td>
									<td>2.97(0.273)</td>
									<td>8.21 (0.410)</td>
									<td>8.21 (0.410)</td>
									<td>8.21 (0.410)</td>
								</tr>
								<tr>
									<td>regdanvimab 80 mg/kg</td>
									<td>2.83</td>
									<td>6.84 (0.461)</td>
									<td>7.70 (0.088)</td>
									<td>7.30 (0.088)</td>
								</tr>
								<tr>
									<td>Placebo</td>
									<td>4.13 (0.695)</td>
									<td>7.41</td>
									<td>7.41</td>
									<td>7.41</td>
								</tr>
								<tr>
									<td class="cate" rowspan="4">Area under curve<br>of viral titer<br>(log<span class="sb-script">10</span> cp/ml*day)</td>
									<td>regdanvimab 20 mg/kg</td>
									<td>N/A</td>
									<td>28.42</td>
									<td>29.09</td>
									<td>31.15</td>
								</tr>
								<tr>
									<td>regdanvimab 40 mg/kg</td>
									<td>9.35</td>
									<td>31.83</td>
									<td>31.83</td>
									<td>31.83</td>
								</tr>
								<tr>
									<td>regdanvimab 80 mg/kg</td>
									<td>7.63</td>
									<td>32.24</td>
									<td>33.62</td>
									<td>33.62</td>
								</tr>
								<tr>
									<td>Placebo</td>
									<td>13.70</td>
									<td>44.22</td>
									<td>44.22</td>
									<td>44.22</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
	</section>
	<!--cont-d-->
	<section id="sec03" class="cont-e el">
		<div class="inner">
			<h2 class="cont-tit">Part 1 of Phase II/III Global Pivotal<span>¹</span></h2>
			<div class="cont-sec">
				<h3 class="sub-tit">Study Design</h3>
				<div class="cont-indt">
					<ul class="cont-list">
						<li><b>A Randomized, Parallel-group, Placebo-controlled, Double-blind study</b></li>
						<li>The data supporting regdanvimab's authorization are based on interim data from one Phase 2 trial of 307 mild to moderate COVID-19  patients.</li> 
						<li>This study is designed to evaluate the efficacy and safety of regdanvimab in combination with standard of care in outpatients with SARS-CoV-2 infection.</li>
						<li>This study began in September 2020 with the primary endpoint reached in December 2020 and the completion of the study is estimated to be in September 2021. 
						</li>
					</ul>
					<ul class="part-img">
						<li><img src="/img/providers/part_img01.png"></li>
						<li><img src="/img/providers/part_img02.png"></li>
					</ul>
				</div>
			</div>
			<!--Study Design-->
			<div class="cont-sec">
				<h3 class="sub-tit">Primary Objective</h3>
				<div class="cont-box cont-indt">
					<ul class="cont-list">
						<li>
							<b class="p-bk">Part 1 (Phase II) : </b>
							To assess that regdanvimab has the potential therapeutic efficacy relative to Placebo as determined by time to recovery
						</li>
						<li>
							<b class="p-bk">Part 2 (Phase III) : </b>
							To demonstrate that regdanvimab has the clinical meaningful therapeutic efficacy relative to Placebo as determined by the time to recovery
						</li>
					</ul>
				</div>
			</div>
			<!--Primary Objective-->
			<div class="cont-sec">
				<h3 class="sub-tit">Primary Endpoints</h3>
				<div class="cont-box cont-indt">
					<b class="p-bk mg06">Part 1 (Phase II) : </b>
					<ul class="cont-list mg20">
						<li>
							Proportion of patient with negative conversion in nasopharyngeal swab specimen based on reverse transcription quantitative polymerase chain reaction (RT-qPCR) or cell culture at each visit
						</li>
						<li>Time to negative conversion in nasopharyngeal swab specimen based on RT-qPCR or cell culture</li>
						<li>Time to clinical recovery</li>
						<li>Proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection</li>
					</ul>
					<b class="p-bk mg06">Part 2 (Phase III)</b>
					<ul class="cont-list">
						<li>Proportion of patients with clinical symptom requiring hospitalization, oxygen therapy, or experiencing mortality due to SARS-CoV-2 infection</li>
					</ul>
				</div>
			</div>
			<!--Primary Endpoints-->
			<div class="cont-sec">
				<h3 class="sub-tit">Eligibility Criteria</h3>
				<div class="cont-box cont-indt">
					<div class="dia-wr">
						<div class="list">
							<p class="tit01">Key Inclusion Criteria</p>
							<ul class="cont-list">
								<li>Adult male or female, aged <b>18 years or older</b><li>
								<li>Patient <b>diagnosed with SARS-CoV-2</b> at screening</li>
								<li>
									Patient with oxygen saturation <b>>94%</b> on room air and <b>not requiring supplemental oxygen.</b> Patient with clinical signs of pneumonia but no signs of severe pneumonia at the investigator’s discretion is eligible for this study.
								</li>
								<li>Patient whose <b>onset of symptom is no more than 7 days</b></li>
								<li>
									Patient with 1≥ of the following (but not limited to) SARS-CoV-2 associated symptoms within but not more than 7 days prior to the study drug administration
								</li>
								<li class="blt-none">
									<ul class="s-cont-list">
										<li class="bt-none">
											- Feeling feverish<br>
											- Cough<br>
											- Shortness of breath<br>
											- Sore throat
										</li>
										<li class="bt-none">
											- Body or muscle pain<br>
											- Fatigue<br>
											- Headache
										</li>
									</ul>
									<!--s-cont-list-->
								</li>
							</ul>
							<!--cont-list-->
						</div>
						<div class="list">
							<p class="tit02">Key Exclusion Criteria</p>
							<ul class="cont-list">
								<li>Patient with <b>serious condition</b> (previously or currently hospitalized, or requires hospitalization for treatment of serious SARS-CoV-2 related conditions, respiratory distress with respiratory rate ≥30 breaths/min, requires supplemental oxygen, experience shock, complicated with other organ failure and ICU treatment is needed, or any other conditions suspected of being severe symptoms of SARS-CoV-2)<li>
								<li>
									Patient who has received or has plan to <b>receive any prohibited medications or treatments</b>
								</li>
								<li>
									Patient who has <b>known allergy or hypersensitivity reaction to any monoclonal antibody</b> or to any components of the study drug
								</li>
							</ul>
							<!--cont-list-->
						</div>
					</div>
				</div>
			</div>
			<!--Eligibility Criteria-->
		</div>
	</section>
	<!--cont-e-->
	<section class="cont-f">
		<div class="inner">
			<div class="cont-sec">
				<h3 class="sub-tit">Study Results</h3>
				<h3 class="sub-tit3">Key Demographic Information_Intent-to-Treat Infected (ITTI) set.</h3>
				<div class="cont-box cont-indt">
					<ul class="cont-list">
						<li>Approximately <span class="p-rd">60%</span> of participants are moderate patients with pneumonia symptom.</li>
					</ul>
					<div class="table-wr">
						<table class="table-style02">
							<thead>
								<tr>
									<th>ITTi Population</th>
									<th>Total(N=307)</th>
									<th>regdanvimab 40 mg/kg (N=101)</th>
									<th>regdanvimab 80 mg/kg (N=103)</th>
									<th>regdanvimab Total (N=204)</th>
									<th>Placebo (N=103)</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td class="cate">Mild</td>
									<td>124 (40.4)</td>
									<td>38 (37.6)</td>
									<td>40 (38.8)</td>
									<td>78 (38.2)</td>
									<td>46 (44.7)</td>
								</tr>
								<tr>
									<td class="cate">Moderate (pneumonia)</td>
									<td>182 (59.3)</td>
									<td>62 (61.4)</td>
									<td>63 (61.2)</td>
									<td>125(61.3)</td>
									<td>57(55.3)</td>
								</tr>
							</tbody>
						</table>
					</div>
					<ul class="cont-list">
						<li>The patients having pneumonia symptoms were considered to have moderate disease severity of SARS-CoV-2 infection at Screening.</li>
						<li>Regdanvimab is not authorized with doses of 20 mg/kg and 80 mg/kg.</li>
					</ul>
				</div>
			</div>
			<!---->
			<div class="cont-sec">
				<h3 class="sub-tit3">Efficacy</h3>
				<div class="cont-box cont-indt">
					<h4 class="sub-tit2">Progression Rates to Severe COVID-19 </h4>
					<ul class="cont-list">
						<li>regdanvimab (40mg/kg) treated patients <span class="p-rd">reported reduced progression rates to severe COVID-19 by 54%</span> for patients with mild-to-moderate symptoms and <span class="p-rd">68%</span> for moderate patients aged 50 years and over.</li>
					</ul>
					<div class="table-wr">
						<table class="table-style02">
							<thead>
								<tr>
									<th></th>
									<th>regdanvimab 40 mg/kg (N= 101)</th>
									<th>regdanvimab 80 mg/kg (N= 103)</th>
									<th>regdanvimab Total (N=204)</th>
									<th>Placebo (N=103)</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td class="cate">Total patients</td>
									<td>4/101 (<b class="p-rd">4.0</b>)</td>
									<td>5/103 (4.9)</td>
									<td>9/204 (<b class="p-bk">4.4</b>)</td>
									<td>9/103 (<b class="p-bl">8.7</b>)</td>
								</tr>
								<tr>
									<td class="cate">Moderate (pneumonia)</td>
									<td>4/62 (<b class="p-rd">6.5</b>)</td>
									<td>5/63 (7.9)</td>
									<td>9/125 (<b class="p-bk">7.2</b>)</td>
									<td>9/57 (<b class="p-bl">15.8</b>)</td>
								</tr>
								<tr>
									<td class="cate">Age≥50 Moderate (pneumonia)</td>
									<td>3/40 (<b class="p-rd">7.5</b>)</td>
									<td>4/40 (10.0)</td>
									<td>7/80 (<b class="p-bk">8.8</b>)</td>
									<td>9/38 (<b class="p-bl">23.7</b>)</td>
								</tr>
							</tbody>
						</table>
					</div>
					<ul class="cont-list">
						<li>The patients having pneumonia symptoms were considered to have moderate disease severity of SARS-CoV-2 infection at Screening.</li>
						<li>Regdanvimab is not authorized with doses 80 mg/kg.</li>
					</ul>
				</div>
			</div>
			<!---->
			<div class="cont-sec">
				<div class="cont-box cont-indt">
					<h4 class="sub-tit2 mg10">Time to <span class="p-bl">Clinical Recovery up to Day 14</span></h4>
					<ul class="cont-list">
						<li>The median time to clinical recovery was significantly shorter in the regdanvimab groups compared to the Placebo group.</li>
						<li>6 days shorter in regdanvimab 40 mg/kg group for moderate SARS-CoV-2 infected patients with age ≥50 years.</li>
						<li><b class="p-bk">Greatest benefit was noted in the older population (≥ 50 years old), who are more vulnerable to SARS-CoV-2 infection.</b></li>
					</ul>
					<div class="table-wr">
						<table class="table-style02">
							<colgroup>
								<col width="16%">
								<col width="16%">
								<col width="16%">
								<col width="16%">
								<col width="16%">
								<col width="16%">
							</colgroup>
							<thead>
								<tr>
									<th>Total patients</th>
									<th>regdanvimab<br>40 mg/kg (N=101)</th>
									<th>regdanvimab<br>80 mg/kg (N= 103)</th>
									<th>regdanvimab<br>Total (N=204)</th>
									<th>Placebo<br>(N=103)</th>
									<th class="th-bg-g">regdanvimab</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td class="cate">Recovered Patients</td>
									<td>73/95 (76.8%)</td>
									<td>72/92 (78.3%)</td>
									<td>145/187 (77.5%)</td>
									<td>62/98 (63.3%)</td>
									<td rowspan="4"><b class="p-rd">8.8 → 5.4<br>(3.4 days Difference)</b></td>
								</tr>
								<tr>
									<td class="cate">Median (95% CI)</td>
									<td><b>5.35</b> (3.97, 6.78)</td>
									<td><b>6.23</b> (5.53, 7.85)</td>
									<td><b>5.72</b> (5.15, 7.00)</td>
									<td><b>8.77</b> (6.72, 11.73)</td>
								</tr>
								<tr>
									<td class="cate">Clinical Recovery Ratio</td>
									<td><b>1.562</b> (1.11, 2.20)</td>
									<td><b>1.429</b> (1.02, 2.01)</td>
									<td><b>1.489</b> (1.11, 2.01)</td>
									<td></td>
								</tr>
								<tr>
									<td class="cate">p-value</td>
									<td><b class="p-rd">0.0097*</b></td>
									<td><b class="p-rd">0.0392*</b></td>
									<td><b class="p-rd">0.0084*</b></td>
									<td></td>
								</tr>
							</tbody>
						</table>
						<table class="table-style02">
							<colgroup>
								<col width="16%">
								<col width="16%">
								<col width="16%">
								<col width="16%">
								<col width="16%">
								<col width="16%">
							</colgroup>
							<thead>
								<tr>
									<th>Moderate Patients<br>(pneumonia)</th>
									<th>regdanvimab<br>40 mg/kg (N=62)</th>
									<th>regdanvimab<br>80 mg/kg (N=63)</th>
									<th>regdanvimab<br>Total (N=125)</th>
									<th>Placebo<br>(N=57)</th>
									<th class="th-bg-g">Difference with<br>Placebo group</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td class="cate">Recovered Patients</td>
									<td>44/60 (73.3%)</td>
									<td>37/54 (68.5%)</td>
									<td>81/114 (71.1%)</td>
									<td>30/53 (56.6%)</td>
									<td rowspan="3"><b class="p-rd">10.8 → 5.7<br>(5.1 days Difference)</b></td>
								</tr>
								<tr>
									<td class="cate">Median (95% CI, Day)</td>
									<td><b>5.73</b> (4.13, 7.33)</td>
									<td><b>7.30</b> (5.58, 10.72)</td>
									<td><b>6.52</b> (5.53, 7.69)</td>
									<td><b>10.81</b> (6.81, N.C.)</td>
									
								</tr>
								<tr>
									<td class="cate">Clinical Recovery Ratio</td>
									<td>1.689 (1.06,2.70)</td>
									<td>1.347 (0.83,2.18)</td>
									<td>1.511 (0.99,2.30)</td>
									<td></td>
								</tr>
							</tbody>
						</table>
						<table class="table-style02">
							<colgroup>
								<col width="16%">
								<col width="16%">
								<col width="16%">
								<col width="16%">
								<col width="16%">
								<col width="16%">
							</colgroup>
							<thead>
								<tr>
									<th>Age≥50 Moderate Patients<br>(pneumonia)</th>
									<th>regdanvimab<br>40 mg/kg(N=40)</th>
									<th>regdanvimab<br>80 mg/kg(N=40)</th>
									<th>regdanvimab<br>Total(N=80)</th>
									<th>Placebo<br>(N=38)</th>
									<th class="th-bg-g">Difference with<br>Placebo group</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td class="cate">Recovered Patients</td>
									<td>25/38 (65.8)</td>
									<td>24/35 (68.6)</td>
									<td>49/73 (67.1)</td>
									<td>18/35 (51.4)</td>
									<td rowspan="3"><b class="p-rd">13.0 → 6.6<br>(6.4 days Difference)</b></td>
								</tr>
								<tr>
									<td class="cate">Median (95% CI); Day</td>
									<td><b>6.64</b> (4.13, 11.94)</td>
									<td><b>7.29</b> (5.54, 12.33)</td>
									<td><b>6.79</b> (5.50, 10.72)</td>
									<td><b>12.97</b> (6.81, N.C.)</td>
								</tr>
								<tr>
									<td class="cate">Clinical Recovery Ratio (95% CI)</td>
									<td>1.584 (0.86,2.91)</td>
									<td>1.504 (0.81,2.78)</td>
									<td>1.545 (0.90,2.65)</td>
									<td></td>
								</tr>
							</tbody>
						</table>
					</div>
					<ul class="cont-list">
						<li><b class="p-bk">*: Nominal significance</b></li>
						<li>The patients having pneumonia symptoms were considered to have moderate disease severity of SARS-CoV-2 infection at Screening</li>
						<li>Definition of clinical recovery : Clinical recovery is defined by all symptoms on the SARS-CoV-2 infection symptom Checklist (consists of 7 symptoms and the intensity of patient’s self-aware for each. symptom) are recorded as ‘absent or mild in intensity’ for at least 24 hours.</li>
						<li>Regdanvimab is not authorized with doses of 80 mg/kg</li>
						<li class="bt-none p-gr">CI, confidence interval.</li>
					</ul>
				</div>
			</div>
			<!---->
			<div class="cont-sec">
				<h3 class="sub-tit3">Mean (± SE) Change from Baseline of Viral Load titer (in log10cp/mL) (All patients)</h3>
				<div class="cont-box cont-indt">	
					<ul class="cont-list">
						<li class="p-bk">Greater reductions from baseline viral load were shown in regdanvimab groups compared to the Placebo group</li>
					</ul>
					<div class="img-sec"><img src="/img/providers/graph_img02.jpg"></div>
					<ul class="cont-list">
						<li>Regdanvimab is not authorized with doses of 80 mg/kg</li>
						<li class="blt-none">SE, standard error.</li>
					</ul>
				</div>
			</div>
			<div class="cont-sec">
				<h3 class="sub-tit3" style="margin-left:0;">Time-Weighted Average Change from Baseline for Viral Shedding (in log10cp/mL) (Day 7 & Day 10)</h3>
				<div class="cont-box cont-indt">
					<ul class="cont-list">
						<li>At Day 7 and Day 10, regdanvimab group showed difference in viral shedding from placebo groups, and this result was statistically significant.</li>
					</ul>
					<div class="table-wr">
						<table class="table-style02">
							<colgroup>
								<col width="20%">
								<col width="20%">
								<col width="20%">
								<col width="20%">
								<col width="20%">
							</colgroup>
							<thead>
								<tr>
									<th></th>
									<th>regdanvimab 40mg/kg<br>(N=101)</th>
									<th>regdanvimab 80mg/kg<br>(N=103)</th>
									<th>Pooled regdanvimab</th>
									<th>Placebo<br>(N=103)</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td class="al-l" colspan="5">Time-Weighted Average Change from Baseline through Day 7</td>
								</tr>
								<tr>
									<td class="al-l">N</td>
									<td>96</td>
									<td>101</td>
									<td>197</td>
									<td>103</td>
								</tr>
								<tr>
									<td class="al-l">Least Square Mean (SE)</td>
									<td>-1.72 (0.084)</td>
									<td>-1.75 (0.082)</td>
									<td>-1.74 (0.0065)</td>
									<td>-1.33 (0.082)</td>
								</tr>
								<tr>
									<td class="al-l">95% CI</td>
									<td>-1.33 (0.082)</td>
									<td>-1.33 (0.082)</td>
									<td>-1.87, -1.61</td>
									<td>-1.49, -1.16</td>
								</tr>
								<tr>
									<td class="al-l bd-blue" colspan="5">Difference vs Placebo by Day 7</td>
								</tr>
								<tr>
									<td class="al-l">Least Square Mean (SE)</td>
									<td><b>-0.40 (0.104)</b></td>
									<td><b>-0.43 (0.103)</b></td>
									<td class="bd-blue" ><b>-0.41 (0.089)</b></td>
									<td></td>
								</tr>
								<tr>
									<td class="al-l" >95% CI</td>
									<td>-0.60, -0.19</td>
									<td>-0.63, -0.22</td>
									<td class="bd-blue" >-0.59, -0.24</td>
									<td></td>
								</tr>
								<tr>
									<td class="al-l">P-value</td>
									<td>0.0002</td>
									<td>&lt;0.0001</td>
									<td class="bd-blue" ><b class="p-rd">&lt;0.0001</b></td>
									<td></td>
								</tr>
								<tr>
									<td class="al-l bd-blue" colspan="5">Time-Weighted Average Change from Baseline through Day 10</td>
								</tr>
								<tr>
									<td class="al-l">N</td>
									<td>96</td>
									<td>101</td>
									<td>197</td>
									<td>103</td>
								</tr>
								<tr>
									<td class="al-l">Least Square Mean (SE)</td>
									<td>-2.13 (0.085)</td>
									<td>-2.21 (0.083)</td>
									<td>-2.17 (0.065)</td>
									<td>-1.78 (0.083)</td>
								</tr>
								<tr>
									<td class="al-l">95% CI</td>
									<td>-2.30, -1.96</td>
									<td>-2.37, -2.04</td>
									<td>-2.30, -2.04</td>
									<td>-1.94, -1.62</td>
								</tr>
								<tr>
									<td class="al-l bd-blue"  colspan="5">Difference vs Placebo by Day 10</td>
								</tr>
								<tr>
									<td class="al-l">Least Square Mean (SE)</td>
									<td><b>-0.35 (0.105)</b></td>
									<td><b>-0.43 (0.103)</b></td>
									<td class="bd-blue" ><b>-0.39 (0.090)</b></td>
									<td></td>
								</tr>
								<tr>
									<td class="al-l">95% CI</td>
									<td>-0.56, -0.15</td>
									<td>-0.63, -0.22</td>
									<td class="bd-blue" >-0.57, -0.21</td>
									<td></td>
								</tr>
								<tr>
									<td class="al-l">P-value</td>
									<td>0.0009</td>
									<td>&lt;0.0001</td>
									<td class="bd-blue" ><b class="p-rd">&lt;0.0001</b></td>
									<td></td>
								</tr>
								<tr>
									<td class="al-l" colspan="5">Note: P-value from stratified log-rank test stratified by age (≥60 years vs. &lt;60 years), baseline comorbidities (Yes vs. No) and region are presented.<br> Patients who have negative or missing result at baseline and do not have positive at Day 2 are excluded in this analysis.</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
			<div class="cont-sec">
				<h3 class="sub-tit3">Safety</h3>
				<div class="cont-box cont-indt">
					<ul class="cont-list">
						<li>With regdanvimab receiving a positive safety profile and no drug-related serious adverse events reported.</li>
					</ul>
					<div class="table-wr">
						<table class="table-style02">
							<thead>
								<tr>
									<th colspan="2">Safety Population</th>
									<th>regdanvimab 40 mg/kg (N=105)</th>
									<th>regdanvimab 80 mg/kg (N=110)</th>
									<th>regdanvimab Total (N=215)</th>
									<th>Placebo (N=110)</th>
								</tr>
							</thead>
							<tbody>
								<tr>
									<td class="cate" rowspan="2">No. of patients<br>with 1+ Adverse Event (AE)</td>
									<td>Total</td>
									<td>31 (29.5)</td>
									<td>27 (24.5)</td>
									<td>58 (<b class="p-rd">27.0</b>)</td>
									<td>34 (<b class="p-rd">30.9</b>)</td>
								</tr>
								<tr>
									<td>Related</td>
									<td>7 (6.7)</td>
									<td>5 (4.5)</td>
									<td>12 (<b class="p-rd">5.6</b>)</td>
									<td>34 (<b class="p-rd">4.5</b>)</td>
								</tr>
								<tr>
									<td class="cate">No. of patients with 1+ Serious Adverse Event</td>
									<td>Total</td>
									<td>0</td>
									<td>0</td>
									<td>0</td>
									<td>0</td>
								</tr>
								<tr>
									<td class="cate">Infusion Related Reaction</td>
									<td>Total</td>
									<td>1 (1.0)</td>
									<td>0</td>
									<td>1 <b class="p-rd">(0.5)</b></td>
									<td>2 <b class="p-rd">(1.8)</b></td>
								</tr>
								<tr>
									<td class="cate">Dropout Due to AE</td>
									<td>Total</td>
									<td>0</td>
									<td>0</td>
									<td>0</td>
									<td>0</td>
								</tr>
							</tbody>
						</table>
					</div>
					<ul class="cont-list">
						<li>The safety results confirmed that the regdanvimab was well tolerated and safety profile following regdanvimab administration did not show any unexpected safety issue.</li>
						<li>Overall rate of infusion related reaction was low and no treatment-emergent serious adverse events or deaths were reported during the study.</li>
						<li>the anti-drug antibody positive rate was low, and no suspicious antibody-dependent enhancement event was reported during the study.</li>
					</ul>
				</div>
			</div>
			<!---->
			<div class="cont-sec">
				<h3 class="sub-tit3">Reference</h3>
				<p class="cont-indt">1. Data on File, Celltrion Healthcare</p>
			</div>
		</div>
	</section>
	<!--cont-f-->
	<section id="sec04" class="cont-c el">
		<div class="inner">
			<h2 class="cont-tit">In-vitro Plaque Reduction Neutralizing Test (PRNT)<span>¹</span></h2>
			<div class="cont-sec">
				<h3 class="sub-tit">Regdanvimab demonstrate neutralizing capability against the UK variant (B.1.1.7)</h3>
				<ul class="cont-list cont-indt">
					<li>Regdanvimab neutralizes the SARS-CoV-2 variants first identified in the UK in addition to seven variant genome mutations of SARS-CoV-2 (variants S·L·V·G·GH·GV·GR).</li>
					<li>Cocktail therapy of regdanvimab with CT-P63(#32 antibody candidate) demonstrated neutralizing capability across all the variants tested (GH/UK variant/RSA variant).
					</li>
				</ul> 
			</div>
			<div class="cont-box cont-indt">
				<div class="table-wr">
					<table class="table-style02">
						<thead>
							<tr>
								<th>mAbs</th>
								<th>Virus</th>
								<th>IC<span class="s-txt">50</span> (ng/ml)</th>
								<th>IC<span class="s-txt">90</span> (ng/ml)</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td class="cate" rowspan="4">regdanviamb</td>
								<td>GV Type</td>
								<td>4.61</td>
								<td>14.65</td>
							</tr>
							<tr>
								<td>UK variant</td>
								<td>3.77</td>
								<td>40.86</td>
							</tr>
							<tr>
								<td>South African variant</td>
								<td>> 1000</td>
								<td>> 1000</td>
							</tr>
							<tr>
								<td>BRA variant (P2)</td>
								<td>14.62</td>
								<td>62.29</td>
							</tr>
							<tr>
								<td class="cate" rowspan="4">CT-P63 (# 32)</td>
								<td>GR Type</td>
								<td>68.94</td>
								<td>1825</td>
							</tr>
							<tr>
								<td>GH Type</td>
								<td>169.2</td>
								<td>820</td>
							</tr>
							<tr>
								<td>UK variant</td>
								<td>22.46</td>
								<td>130.9</td>
							</tr>
							<tr>
								<td>SA variant</td>
								<td>24.45</td>
								<td>59.78</td>
							</tr>
							<tr>
								<td class="cate">regdanvimab + CT-P63</td>
								<td>SA variant</td>
								<td>58.89</td>
								<td>448</td>
							</tr>
						</tbody>
					</table>
					<p style="margin-top:1em;">SA, South Africa; IC<span class="s-txt">50</span>, half‐maximal viral inhibitory concentration; IC<span class="s-txt">90</span>, 9× IC<span class="s-txt">50</span></p>
				</div>
			</div>
		</div>
	</section>
</div> 
<?php
include_once(G5_PATH.'/tail.php');
?>